XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue (Tables)
9 Months Ended
Sep. 30, 2024
Revenue  
Schedule of revenue recognized from collaborative arrangements

Three Months Ended September 30, 

Nine Months Ended September 30, 

(In thousands)

2024

2023

2024

2023

Viatris collaboration agreement – Amounts receivable from Viatris

$

16,868

$

15,687

$

45,627

$

39,841

Three Months Ended September 30, 

Nine Months Ended September 30, 

(In thousands)

  

2024

  

2023

    

2024

  

2023

YUPELRI net sales (Theravance Biopharma implied 35%)

$

21,766

$

20,414

$

60,181

$

56,111

Summary of the reductions to R&D costs related to reimbursement payments

Three Months Ended September 30, 

Nine Months Ended September 30, 

(In thousands)

    

2024

    

2023

2024

    

2023

Viatris

$

$

1,340

$

485

$

5,041